Trial Profile
A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines DNA.HTI, MVA.HTI and ChAdOx1.HTI in Early Treated HIV-1 Positive Individuals
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Apr 2024
Price :
$35
*
At a glance
- Drugs HTI immunogen (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms AELIX-002
- Sponsors Aelix Therapeutics
- 06 Mar 2024 Results exploring humoral, innate, and T cell responses during ATI presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
- 01 Dec 2022 Results of post-hoc analysis assessing safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection published in the Nature Medicine
- 07 Apr 2021 Status changed from active, no longer recruiting to completed.